Abstract
Background: Hepatocellular carcinoma (HCC) has been the fifth most common malignancy worldwide and is particularly endemic in Asia, accounting for around 80% of new cases around the world. Currently, with many new studies and evidences coming into being in Asia, various HCC guidelines have been newly issued or updated. The aim of the present study is to incorporate new evidence on the management of HCC by assessing and comparing the main Asian guidelines. Methods: Electronic databases of MEDLINE, the Chinese SinoMed and the Japanese CiNii were systematically searched. AGREE II instrument was utilized for the quality assessment of guidelines. Results: A total of 11 main Asian guidelines were included. There still remain variances in guideline structures and certain contents. We briefly compared the guidelines and summarized the newly updated recommendations to help hepatobiliary surgeons to catch the latest information. Conclusions: The present review might help focus and target advocacy to improve clinical management of HCC. Further research and more straightforward guidelines are essential to improve the prognosis of HCC in the future.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
